Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab (AK112) + Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced ESCC
NCT07385001Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Tangdu Hospital. Primary endpoints: Dose-Limiting Toxicity at 1 year, Incidence and Severity of Adverse Events at 1 year and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07385001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385001.